nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.08.2014 | Review

Amniotic fluid-derived mesenchymal stem cells: characteristics and therapeutic applications

verfasst von: Jun Zhou, Dejun Wang, Tian Liang, Qiuyan Guo, Guangmei Zhang

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Amniotic fluid mesenchymal stem cells (AF-MSCs) are promising candidates for cell-based therapy. This review presents a comprehensive overview of the features and therapeutic applications of these cells.

Methods

This is a literature review combined with experience of practice.

Conclusion

Although the long-term risks of AF-MSCs require further investigation, these cells are increasing in popularity in the fields of regenerative medicine and targeting therapy because of their unique properties.

Kang NH, Hwang KA, Kim SU, Kim YB, Hyun SH, Jeung EB, Choi KC (2012) Potential antitumor therapeutic strategies of human amniotic membrane and amniotic fluid-derived stem cells. Cancer Gene Ther 19(8):517–522. doi:10.1038/cgt.2012.30 PubMedCrossRef

Bitsika V, Roubelakis MG, Zagoura D, Trohatou O, Makridakis M, Pappa KI, Marini FC, Vlahou A, Anagnou NP (2012) Human amniotic fluid-derived mesenchymal stem cells as therapeutic vehicles: a novel approach for the treatment of bladder cancer. Stem Cells Dev 21(7):1097–1111. doi:10.1089/scd.2011.0151 PubMedCrossRef

Ferroni L, Gardin C, Tocco I, Epis R, Casadei A, Vindigni V, Mucci G, Zavan B (2012) Potential for neural differentiation of mesenchymal stem cells. Adv Biochem Eng Biotechnol. doi:10.1007/10_2012_152

Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L (2006) Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 5(3):755–766. doi:10.1158/1535-7163.MCT-05-0334 PubMedCrossRef

Marappagounder D, Somasundaram I, Janvikula RS, Dorairaj S (2012) Long-term culture optimization of human omentum fat-derived mesenchymal stem cells. Cell Biol Int 36(11):1029–1036. doi:10.1042/CBI20120201 PubMedCrossRef

Tsai MS, Lee JL, Chang YJ, Hwang SM (2004) Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod 19(6):1450–1456. doi:10.1093/humrep/deh279 PubMedCrossRef

Antonucci I, Stuppia L, Kaneko Y, Yu S, Tajiri N, Bae EC, Chheda SH, Weinbren NL, Borlongan CV (2011) Amniotic fluid as a rich source of mesenchymal stromal cells for transplantation therapy. Cell Transplant 20(6):789–795. doi:10.3727/096368910X539074 PubMedCrossRef

Kim J, Lee Y, Kim H, Hwang KJ, Kwon HC, Kim SK, Cho DJ, Kang SG, You J (2007) Human amniotic fluid-derived stem cells have characteristics of multipotent stem cells. Cell Prolif 40:75–90PubMedCrossRef

Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107(1):367–372. doi:10.1182/blood-2005-07-2657 PubMedCrossRef

10.

Siegel G, Schafer R, Dazzi F (2009) The immunosuppressive properties of mesenchymal stem cells. Transplantation 87(9 Suppl):S45–S49. doi:10.1097/TP.0b013e3181a285b0 PubMedCrossRef

11.

Johnson1 MH (2008) Human ES cells and a blastocyst from one embryo—exciting science but conflicting ethics. Cell Stem Cell. doi:10.1016/j.stem.2008.01.021

12.

Prusa AR, Marton E, Rosner M, Bernaschek G, Hengstschlager M (2003) Oct-4-expressing cells in human amniotic fluid: a new source for stem cell research? Hum Reprod 18(7):1489–1493. doi:10.1093/humrep/deg279 PubMedCrossRef

13.

De Coppi P, Bartsch G, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ, Furth ME, Soker S, Atala A (2007) Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 25(1):100–106. doi:10.1038/nbt1274 PubMedCrossRef

14.

In’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, Kanhai HH (2004) Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 22(7):1338–1345. doi:10.1634/stemcells.2004-0058 CrossRef

15.

Mauro A, Turriani M, Ioannoni A, Russo V, Martelli A, Di Giacinto O, Nardinocchi D, Berardinelli P (2010) Isolation, characterization, and in vitro differentiation of ovine amniotic stem cells. Vet Res Commun 34(Suppl 1):S25–S28. doi:10.1007/s11259-010-9393-2 PubMedCrossRef

16.

Pesce M, Schöler HR (2001) Oct-4—gatekeeper in the beginnings of mammalian development. Stem Cells 19:271–278PubMedCrossRef

17.

Cananzi M, Atala A, De Coppi P (2009) Stem cells derived from amniotic fluid—new potentials in regenerative medicine. Ethics Biosci Life 4(1):17–27

18.

Rennie K, Gruslin A, Hengstschlager M, Pei D, Cai J, Nikaido T, Bani-Yaghoub M (2012) Applications of amniotic membrane and fluid in stem cell biology and regenerative medicine. Stem Cells Int 2012:721538. doi:10.1155/2012/721538 PubMedCentralPubMedCrossRef

19.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315–317. doi:10.1080/14653240600855905 PubMedCrossRef

20.

S-z Huo, Shi P, Pang X-n (2010) Culture and identification of human amniotic mesenchymal stem cells. Chin Med Sci J 25(4):211–214. doi:10.1016/s1001-9294(11)60004-7 CrossRef

21.

Bai J, Hu Y, Wang YR, Liu LF, Chen J, Su SP, Wang Y (2012) Comparison of human amniotic fluid-derived and umbilical cord Wharton’s jelly-derived mesenchymal stromal cells: characterization and myocardial differentiation capacity. J Geriatr Cardiol JGC 9(2):166–171. doi:10.3724/SP.J.1263.2011.12091 CrossRef

22.

HU Jie YANG Li-Juan, LIU Hui, WANG Yun-Fang (2009) Fractional cultivation, identification and immunosuppression of amniotic fluid-derived human mesenchymal stem cells. Bull Acad Mil Med Sci 33(2)

23.

Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoorn PC, Szuhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop DJ, Fibbe WE, Blazar BR (2007) Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25(2):371–379. doi:10.1634/stemcells.2005-0620 PubMedCrossRef

24.

Wang Y, Bai J, Chen J, Liu L, Wang Y (2012) Comparative studies on different cryopreservation protocols of human amniotic fluid-derived mesenchymal stem cells. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chin J Reparative Reconstr Surg 26(2):141–145

25.

Carraro G, Perin L, Sedrakyan S, Giuliani S, Tiozzo C, Lee J, Turcatel G, De Langhe SP, Driscoll B, Bellusci S, Minoo P, Atala A, De Filippo RE, Warburton D (2008) Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages. Stem Cells 26(11):2902–2911. doi:10.1634/stemcells.2008-0090 PubMedCentralPubMedCrossRef

26.

Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F (2005) Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105(7):2821–2827. doi:10.1182/blood-2004-09-3696 PubMedCrossRef

27.

Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111(3):1327–1333. doi:10.1182/blood-2007-02-074997 PubMedCrossRef

28.

Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE (2006) Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108(6):2114–2120. doi:10.1182/blood-2005-11-011650 PubMedCentralPubMedCrossRef

29.

Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371(9624):1579–1586. doi:10.1016/s0140-6736(08)60690-x PubMedCrossRef

30.

Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J (2005) Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 106(13):4057–4065. doi:10.1182/blood-2005-03-1004 PubMedCrossRef

31.

Cowan CA, Klimanskaya I, McMahon J, Atienza J, Witmyer J, Zucker JP, Wang S, Morton CC, McMahon AP, Powers D, Melton DA (2004) Derivation of embryonic stem-cell lines from human blastocysts. N Engl J Med 350(13):1353–1356. doi:10.1056/NEJMsr040330 PubMedCrossRef

32.

Amit M, Carpenter MK, Inokuma MS, Chiu CP, Harris CP, Waknitz MA, Itskovitz-Eldor J, Thomson JA (2000) Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol 227(2):271–278. doi:10.1006/dbio.2000.9912 PubMedCrossRef

33.

Aguilar S (2007) Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells 25(1586–1594):2006 10.1634/stemcells-0762

34.

Zimmermann S, Voss M, Kaiser S, Kapp U, Waller CF, Martens UM (2003) Lack of telomerase activity in human mesenchymal stem cells. Leuk Off J Leuk Soc Am Leuk Res Fund UK 17(6):1146–1149. doi:10.1038/sj.leu.2402962 CrossRef

35.

Roubelakis MG, Bitsika V, Zagoura D, Trohatou O, Pappa KI, Makridakis M, Antsaklis A, Vlahou A, Anagnou NP (2011) In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells. J Cell Mol Med 15(9):1896–1913. doi:10.1111/j.1582-4934.2010.01180.x PubMedCrossRef

36.

Sessarego N, Parodi A, Podesta M, Benvenuto F, Mogni M, Raviolo V, Lituania M, Kunkl A, Ferlazzo G, Bricarelli FD, Uccelli A, Frassoni F (2008) Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. Haematologica 93(3):339–346. doi:10.3324/haematol.11869 PubMedCrossRef

37.

Moschidou D, Mukherjee S, Blundell MP, Drews K, Jones GN, Abdulrazzak H et al (2012) Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. Mol Ther 20:1953–1967

38.

Parekkadan B, Milwid JM (2010) Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 12(1):87–117. doi:10.1146/annurev-bioeng-070909-105309 PubMedCentralPubMedCrossRef

39.

Kunter U, Rong S, Boor P, Eitner F, Muller-Newen G, Djuric Z, van Roeyen CR, Konieczny A, Ostendorf T, Villa L, Milovanceva-Popovska M, Kerjaschki D, Floege J (2007) Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol JASN 18(6):1754–1764. doi:10.1681/ASN.2007010044 CrossRef

40.

Chiavegato A, Bollini S, Pozzobon M, Callegari A, Gasparotto L, Taiani J, Piccoli M, Lenzini E, Gerosa G, Vendramin I, Cozzi E, Angelini A, Iop L, Zanon GF, Atala A, De Coppi P, Sartore S (2007) Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat. J Mol Cell Cardiol 42(4):746–759. doi:10.1016/j.yjmcc.2006.12.008 PubMedCrossRef

41.

Weber B, Emmert MY, Behr L, Schoenauer R, Brokopp C, Drogemuller C, Modregger P, Stampanoni M, Vats D, Rudin M, Burzle W, Farine M, Mazza E, Frauenfelder T, Zannettino AC, Zund G, Kretschmar O, Falk V, Hoerstrup SP (2012) Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal circulation. Biomaterials 33(16):4031–4043. doi:10.1016/j.biomaterials.2011.11.087 PubMedCrossRef

42.

SHAUN M.Kunisaki DAF (2006) Fetal tracheal reconstruction with cartilaginous grafts engineered from mesenchymal amniocytes. Journal oF Pediatric Surgery 41:675-682

43.

Djouad F, Mrugala D, Noël D, Jorgensen C (2006) Engineered mesenchymal stem cells for cartilage repair. Regen Med 1(4):529–537. doi:10.2217/17460751.1.4.529 PubMedCrossRef

44.

Delo DM, Guan X, Wang Z, Groban L, Callahan M, Smith T, Sane DC, Payne RM, Atala A, Soker S (2011) Calcification after myocardial infarction is independent of amniotic fluid stem cell injection. Cardiovasc Pathol Off J Soc Cardiovasc Pathol 20(2):e69–e78. doi:10.1016/j.carpath.2010.03.001 CrossRef

45.

De Coppi P, Callegari A, Chiavegato A, Gasparotto L, Piccoli M, Taiani J, Pozzobon M, Boldrin L, Okabe M, Cozzi E, Atala A, Gamba P, Sartore S (2007) Amniotic fluid and bone marrow derived mesenchymal stem cells can be converted to smooth muscle cells in the cryo-injured rat bladder and prevent compensatory hypertrophy of surviving smooth muscle cells. J Urol 177(1):369–376. doi:10.1016/j.juro.2006.09.103 PubMedCrossRef

46.

Laura Perin SS (2010) Protective effect of human amniotic fluid stem cells in an immunodeficient mouse model of acute tubular necrosis. PLoS One 5(2). doi:10.1371/journal.pone.0009357.g001

47.

Cananzi M, De Coppi P (2012) CD117+ amniotic fluid stem cells: state of the art and future perspectives. Organogenesis 8(3):77–88. doi:10.4161/org.22426

48.

Klemmt PAB, Vafaizadeh V, Groner B (2010) Murine amniotic fluid stem cells contribute mesenchymal but not epithelial components to reconstituted mammary ducts. Stem Cell Res Ther 1(3):20. doi:10.1186/scrt20 PubMedCentralPubMedCrossRef

49.

Gran SED (1996) Why do so many cancer patients fail to respond to interferon therapy. J Interferon Cytokine Res 16:275–281CrossRef

50.

Bexell D, Scheding S, Bengzon J (2010) Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther 18(6):1067–1075. doi:10.1038/mt.2010.58 PubMedCentralPubMedCrossRef

51.

Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY (2000) Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 97(23):12846–12851. doi:10.1073/pnas.97.23.12846 PubMedCentralPubMedCrossRef

52.

Rachakatla RS, Marini F, Weiss ML, Tamura M, Troyer D (2007) Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther 14(10):828–835. doi:10.1038/sj.cgt.7701077 PubMedCrossRef

53.

Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65(8):3307–3318PubMed

54.

Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T (2006) Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med 203(5):1235–1247. doi:10.1084/jem.20051921 PubMedCentralPubMedCrossRef

55.

Hung SC, Deng WP, Yang WK, Liu RS, Lee CC, Su TC, Lin RJ, Yang DM, Chang CW, Chen WH, Wei HJ, Gelovani JG (2005) Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res Off J Am Assoc Cancer Res 11(21):7749–7756. doi:10.1158/1078-0432.CCR-05-0876 CrossRef

56.

Lee K, Majumdar MK, Buyaner D, Hendricks JK, Pittenger MF, Mosca JD (2001) Human mesenchymal stem cells maintain transgene expression during expansion and differentiation. Mol Ther J Am Soc Gene Ther 3(6):857–866. doi:10.1006/mthe.2001.0327 CrossRef

57.

Gutova M, Najbauer J, Frank RT, Kendall SE, Gevorgyan A, Metz MZ, Guevorkian M, Edmiston M, Zhao D, Glackin CA, Kim SU, Aboody KS (2008) Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 26(6):1406–1413. doi:10.1634/stemcells.2008-0141 PubMedCrossRef

58.

Menon LG, Picinich S, Koneru R, Gao H, Lin SY, Koneru M, Mayer-Kuckuk P, Glod J, Banerjee D (2007) Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells 25(2):520–528. doi:10.1634/stemcells.2006-0257 PubMedCrossRef

59.

Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, Shi Y, Abbruzzese J, Konopleva M, Andreeff M, Marini FC (2010) Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 12(5):615–625. doi:10.3109/14653241003631815 PubMedCrossRef

60.

Cho JA, Park H, Kim HK, Lim EH, Seo SW, Choi JS, Lee KW (2009) Hyperthermia-treated mesenchymal stem cells exert antitumor effects on human carcinoma cell line. Cancer 115(2):311–323. doi:10.1002/cncr.24032 PubMedCrossRef

61.

Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162):557–563. doi:10.1038/nature06188 PubMedCrossRef

62.

Qiao L, Xu ZL, Zhao TJ, Ye LH, Zhang XD (2008) Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett 269(1):67–77. doi:10.1016/j.canlet.2008.04.032 PubMedCrossRef

Titel: Amniotic fluid-derived mesenchymal stem cells: characteristics and therapeutic applications
verfasst von: Jun Zhou
Dejun Wang
Tian Liang
Qiuyan Guo
Guangmei Zhang
Publikationsdatum: 01.08.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2014
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-014-3231-7

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Embryotransfer erhöht womöglich Leukämierisiko der Kinder

13.05.2024 Assistierte Reproduktion Nachrichten

Reproduktionsmedizinische Techniken haben theoretisch das Potenzial, den epigenetischen Code zu verändern und somit das Krebsrisiko der Kinder zu erhöhen. Zwischen Embryotransfer und Leukämie scheint sich ein solcher Zusammenhang bestätigt zu haben.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Polycystic ovarian syndrome and congenital uterine anomalies: the hidden common player

HPV-related cervical disease and oropharyngeal cancer

Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial

Candida glabrata and pre-term premature rupture of membrane complicating in vitro pregnancy: case report and confirmation of mother to neonate transmission